| Recruiting | Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors NCT07170293 | Tianjin Medical University Second Hospital | Phase 2 |
| Not Yet Recruiting | JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR NCT07510841 | Biotech Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Ea NCT07427186 | Institut Claudius Regaud | N/A |
| Not Yet Recruiting | Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinica NCT07192315 | Assistance Publique Hopitaux De Marseille | N/A |
| Recruiting | An Antibody-armored Dendritic Cell in Patients With Solid Tumors NCT07479667 | Shanghai Cell Therapy Group Co.,Ltd | Phase 1 |
| Recruiting | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663 | Beijing Tide Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | xDRIVE for Florida-based Cancer Patients NCT07167381 | First Ascent Biomedical Inc. | N/A |
| Not Yet Recruiting | Real-life Performance Evaluation of the LiFlow X-ray Platform NCT06999538 | University Hospital, Angers | — |
| Not Yet Recruiting | A Study to Evaluate the Safety and Tolerability of EP0089 NCT07030478 | Ellipses Pharma | Phase 1 / Phase 2 |
| Recruiting | Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors NCT07058948 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Application of the sG8 Scale in Real-World Geriatric Oncology Patients NCT06939764 | Sichuan Cancer Hospital and Research Institute | — |
| Active Not Recruiting | Serum IGF-1 and IGF-1Ec in Malignancy Assessment NCT07151807 | Çanakkale Onsekiz Mart University | — |
| Recruiting | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. NCT06883539 | LaunXP Biomedical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss NCT06614751 | Danatlas Pharmaceuticals Co., Ltd | Phase 1 |
| Terminated | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metasta NCT06630247 | Exelixis | Phase 1 |
| Recruiting | 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study NCT05228106 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | — |
| Recruiting | Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy NCT03514368 | Institut Claudius Regaud | N/A |
| Completed | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors NCT02323191 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Ther NCT02174172 | Hoffmann-La Roche | Phase 1 |
| Completed | Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer NCT01820299 | Medical University of South Carolina | Phase 1 |
| Completed | A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With NCT01301716 | Genentech, Inc. | Phase 1 |
| Completed | GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid NCT01332604 | Genentech, Inc. | Phase 1 |
| Terminated | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanc NCT01296555 | Genentech, Inc. | Phase 1 |
| Completed | A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination Wi NCT01209143 | Genentech, Inc. | Phase 1 |
| Completed | A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Ref NCT01226277 | Genentech, Inc. | Phase 1 |
| Completed | A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in C NCT01139723 | Genentech, Inc. | Phase 1 |
| Completed | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advance NCT01106599 | Genentech, Inc. | Phase 1 |
| Completed | A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors NCT01090960 | Genentech, Inc. | Phase 1 |
| Completed | A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel NCT01075464 | Genentech, Inc. | Phase 1 |
| Completed | A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors Th NCT00968981 | Genentech, Inc. | Phase 1 |
| Completed | A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advan NCT00954642 | Genentech, Inc. | Phase 1 |
| Completed | A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Prese NCT00927589 | Genentech, Inc. | Phase 1 |
| Completed | A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors NCT00909740 | Genentech, Inc. | Phase 1 |
| Completed | A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors NCT00747734 | Genentech, Inc. | Phase 1 |
| Completed | A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therap NCT00876109 | Genentech, Inc. | Phase 1 |
| Completed | A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor NCT01068977 | Genentech, Inc. | Phase 1 |
| Terminated | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Ad NCT00977067 | Genentech, Inc. | Phase 1 |
| Completed | A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patien NCT00907205 | Semafore Pharmaceuticals | Phase 1 |
| Completed | A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Stud NCT00096941 | Genentech, Inc. | Phase 2 |